Our Terms of Service and Privacy Policy have changed.

By continuing to use this site, you are agreeing to the new Privacy Policy and Terms of Service.

AbbVie Inc (NYSE:ABBV)

Delayed Data
As of Feb 12
 +0.40 / +0.77%
Today’s Change
Today|||52-Week Range
Health Technology
Pharmaceuticals: Major

Company Description

AbbVie, Inc. is a research-based biopharmaceutical company. It engages in the discovery, development, manufacture and sale of a broad line of proprietary pharmaceutical products. The company's products are used to treat rheumatoid arthritis, psoriasis, Crohn's disease, HIV, cystic fibrosis complications, low testosterone, thyroid disease, Parkinson's disease, ulcerative colitis, and complications associated with chronic kidney disease, among other indications. It also has a pipeline of new medicines, including various compounds or indications in Phase II or Phase III development across such medical specialties as immunology, renal care, hepatitis C, women's health, oncology, and neuroscience, including multiple sclerosis and Alzheimer's disease. The company was founded on April 10, 2012 and is headquartered in North Chicago, IL.

Contact Information

AbbVie, Inc.
1 North Waukegan Road
North Chicago Illinois 60064-6400
P:(847) 932-7900
Investor Relations:
(847) 935-6722



Other institutional36.14%
Mutual fund holders34.04%
Individual stakeholders0.12%

Top Executives

Richard A. GonzalezChairman & Chief Executive Officer
Azita Saleki-GerhardtSenior Vice President-Operations
William J. ChaseChief Financial Officer & Executive Vice President
Michael E. SeverinoCSO, Executive VP-Research & Development
Karen HaleVP, Chief Compliance & Ethics Officer